GlobalMed Technologies has developed a treatment called PCI that uses ultraviolet irradiation of extracted blood to inactivate viruses like HIV. It has received approval to conduct clinical trials on 100 subjects in South America. The document describes GlobalMed's manufacturing of components for the PCI process and presents results from a clinical study in the Dominican Republic where PCI reduced viral loads and opportunistic infections in HIV/AIDS patients more effectively than antiretroviral drugs. GlobalMed believes its approach can significantly reduce healthcare costs for treating HIV/AIDS.